——Global drug regulation database, from NMPA, FDA, EMA, ICH etc., 7/24 updating, with over 100,000 pages and growing;
——Drug industry WIKI, with 1000+ original knowledge entries, and all pages interlinked;
——Professional online training platform, with 1000+ hours courses covering the whole lifecycle of drugs;
——Based on all above, several softwares as a service (SAAS) for pharmaceuticals are under development and to be launched in 2022.

Who are using Shilin?

——150+ paying organization subscribers and growing;
——Major regulation entities: CDE, CFDI, Shanghai MPA...
——MNCs: Pfizer, Merck, Roche, Norvatis...
——Big Pharmas: Hengrui, BeiGene, Qilu...
——Biotechs：InnoventBio, TopAlliance, Hutchison...
——CXOs: WuXi AppTec, Asymchem, Porton...
——90%+ renewal rate.

What Shilin is going to do for English-speaking subscriber?

——Newsletters, weekly tracking China drug regulation with intros;
——Regulation translations, key drug policies, laws, provisions and guidelines fully and high quality translated;
——Featured topics, overviews and insights from specific perspectives for your in-depth understanding and decision-making;
——ChP English database;

What can we do together?

——Q&A. With expertise specialized in China drug regulation, your questions, we could answer;
——Influence. Your knowledge to share, we could be your platform;
——Consultancy services. Your plans and actions in China market, we could consult;
——Business development. Your business looking for pharmaceutical customers in China, we could be your partner.

We are open to any possibilities and we are looking forward to discuss with you.

Contact us

登录